Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2016

Open Access 01-05-2016 | Breast Oncology

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

Authors: Paul Baron, MD, Peter Beitsch, MD, Danielle Boselli, MSc, James Symanowski, PhD, James V. Pellicane, MD, Jennifer Beatty, MD, Paul Richards, MD, Angela Mislowsky, MD, Charles Nash, MD, Laura A. Lee, MD, Mary Murray, MD, Femke A. de Snoo, MD, PhD, Lisette Stork-Sloots, MSc, Mark Gittleman, MD, Stephanie Akbari, MD, Pat Whitworth, MD

Published in: Annals of Surgical Oncology | Issue 5/2016

Login to get access

Abstract

Background

The prospective Neoadjuvant Breast Symphony Trial (NBRST) study found that MammaPrint/BluePrint functional molecular subtype is superior to conventional immunohistochemistry/fluorescence in situ hybridization subtyping for predicting pathologic complete response (pCR) to neoadjuvant chemotherapy. The purpose of this substudy was to determine if the rate of pCR is affected by tumor size.

Methods

The NBRST study includes breast cancer patients who received neoadjuvant chemotherapy. MammaPrint/BluePrint subtyping classified patients into four molecular subgroups: Luminal A, Luminal B, HER2 (human epidermal growth factor receptor 2), and Basal type. Probability of pCR (ypT0/isN0) as a function of tumor size and molecular subgroup was evaluated.

Results

A total of 608 patients were evaluable with overall pCR rates of 28.5 %. Luminal A and B patients had significantly lower rates of pCR (6.1 and 8.7 %, respectively) than either basal (37.1 %) or HER2 (55.0 %) patients (p < 0.001). The probability of pCR significantly decreased with tumor size >5 cm [p = 0.022, odds ratio (OR) 0.58, 95 % confidence interval (CI) 0.36, 0.93]. This relationship was statistically significant in the Basal (p = 0.026, OR 0.46, 95 % CI 0.23, 0.91) and HER2 (p = 0.039, OR 0.36, 95 % CI 0.14, 0.95) subgroups. In multivariate logistic regression analyses, the dichotomized tumor size variable was not significant in any of the molecular subgroups.

Discussion

Even though tumor size would intuitively be a clinical determinant of pCR, the current analysis showed that the adjusted OR for tumor size was not statistically significant in any of the molecular subgroups. Factors significantly associated with pCR were PR status, grade, lymph node status, and BluePrint molecular subtyping, which had the strongest correlation.
Literature
1.
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRef
2.
Glück S, De Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neo-adjuvant chemotherapy. Breast Cancer Res Treat. 2013;139:759–67.CrossRefPubMed
3.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.CrossRefPubMed
4.
Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30:3242–9.CrossRefPubMedPubMedCentral
5.
Kawajiri H, Takashima T, Aomatsu N, et al. Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer. Oncol Lett. 2014;7:663–8.PubMedPubMedCentral
6.
Whitworth P, Stork-Sloots L, de Snoo FA, et al. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol. 2014;21:3261–7.CrossRefPubMedPubMedCentral
7.
Delahaye L, Wehkamp D, Floore A, et al. Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature. Personalized Med. 2013;10:801–11.CrossRef
8.
Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133:37–47.CrossRefPubMed
9.
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.PubMed
10.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
Metadata
Title
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
Authors
Paul Baron, MD
Peter Beitsch, MD
Danielle Boselli, MSc
James Symanowski, PhD
James V. Pellicane, MD
Jennifer Beatty, MD
Paul Richards, MD
Angela Mislowsky, MD
Charles Nash, MD
Laura A. Lee, MD
Mary Murray, MD
Femke A. de Snoo, MD, PhD
Lisette Stork-Sloots, MSc
Mark Gittleman, MD
Stephanie Akbari, MD
Pat Whitworth, MD
Publication date
01-05-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-5030-1

Other articles of this Issue 5/2016

Annals of Surgical Oncology 5/2016 Go to the issue

Breast Oncology

Fertility Preservation for the Young Breast Cancer Patient

Gastrointestinal Oncology

Computerized System for Staging Peritoneal Surface Malignancies

Pancreatic Tumors

Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds

Melanomas

Prognostic Role of Multiple Lymphatic Basin Drainage in Sentinel Lymph Node-Negative Trunk Melanoma Patients: A Multicenter Study from the Italian Melanoma Intergroup

Gastrointestinal Oncology

Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?

Gastrointestinal Oncology

Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement